AstraZeneca (LSE: AZN) and Daiichi Sankyo (TYO: 4568) have reported positive high-level results from the Phase III TROPION-Breast01 study.
The firms are working together on the development of datopotamab deruxtecan, an investigational TROP2-directed antibody-drug conjugate (ADC).
Following the success of Enhertu (trastuzumab deruxtecan), the companies are hoping to once again tap into a growth area where scientists believe there is huge potential to offer more treatment options.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze